Interview with Khiron Life Sciences Corp.


"I believe that a little by little we are clearing the mist around the accident in the Bial trial and recognizing that FAAH inhibitors display a safe clinical profile. Moreover, these moleculescan solve some of the limitations that working with phytocannabinoids have, like the high hypophilicity, low oral bioavailability and IP protection therefore, I think we are going to see some rethinking of strategies around FAAH Inhibitors, but maybe MGL Inhibitors as well, indicating that inhibiting the degradation of endocannabinoids remains a suitable strategy to pursue clinical development."